Donald J. Lazas

Specialized intestinal metaplasia, dysplasia, and cancer of the esophagus and esophagogastric junction: Prevalence and clinical data

William K. Hirota, Thomas Loughney, Donald J. Lazas et al. · Gastroenterology · 1999 · 511 citations · Full text

Medicine, Oncology, Pathology +16

Randomized, Controlled Trial of the FGF21 Analogue Pegozafermin in NASH

Rohit Loomba, Arun J. Sanyal, Kris V. Kowdley et al. · New England Journal of Medicine · 2023 · 442 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +9

A Phase 2 Double Blinded, Randomized Controlled Trial of Saroglitazar in Patients With Nonalcoholic Steatohepatitis

Mohammad Shadab Siddiqui, Michael O. Idowu, Brian B. Borg et al. · Clinical Gastroenterology and Hepatology · 2020 · 89 citations

Medicine, Pharmacology, Pharmacotherapy +8

Tropifexor plus cenicriviroc combination versus monotherapy in nonalcoholic steatohepatitis: Results from the phase 2b TANDEM study

Quentin M. Anstee, Kathryn Jean Lucas, Sven Francque et al. · Hepatology · 2023 · 65 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +9

Tropifexor, a highly potent FXR agonist, produces robust and dose-dependent reductions in hepatic fat and serum alanine aminotransferase in patients with fibrotic NASH after 12 weeks of therapy: FLIGHT-FXR Part C interim results

Kathryn Jean Lucas, Patricia López, Eric Lawitz et al. · Digestive and Liver Disease · 2020 · 51 citations

Medicine, Pharmacology, Pharmacotherapy +17